Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4336-4341

  Cochlovius, Björn ^a   Kipriyanov, Sergey M ^a   Stassar, Marike J J G ^a   Schuhmacher, Jochen ^a   Benner, Axel ^a   Moldenhauer, Gerhard ^a   Little, Melvyn ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 15E8; MONOCLONAL ANTIBODY CD19; OKT 3; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG DISTRIBUTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIGENS, CD19; ANTIGENS, CD28; ANTIGENS, CD3; BURKITT LYMPHOMA; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; LYMPHOMA, B-CELL; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0034662632     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bispecific antibodies
2. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody
3. Monoclonal antibody-based therapies of leukemia and lymphoma
4. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies
5. 1 fragments
6. Human immune response to monoclonal antibodies
7. New protein engineering approaches to multivalent and bispecific antibody fragments
8. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
9. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells
10. Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: Production of bivalent and biotinylated miniantibodies
11. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
12. Nonparametric estimation from incomplete observations
13. Statistical aspects of the analysis of data from retrospective studies of disease
14. Random-effects models for longitudinal data
15. Crystal structure of a diabody, a bivalent antibody fragment
16. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: Improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv
17. Costimulatory regulation of T cell function
18. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
19. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
20. Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer
21. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
22. High level secretion of a humanized bispecific diabody from Escherichia coli
23. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplanted human Hodgkin's tumors
24. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells
25. Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis
26. Improving the tumor specificity and retention of antibody-based molecules
27. Immunotherapy of B-cell lymphoma with CD3 × 19 bispecific antibodies: Costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells
28. Human melanoma therapy in the SCID mouse: In vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bispecific antibody fragments
29. Serial triggering of many T-cell receptors by a few peptide-MHC complexes
30. Bispecific antibodies in cancer therapy